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Clinical features are indicators of activity  
in common vitiligo
This was a 1-year prospective observational study. Fifty 
patients were included. Lesions were classified as hypo-
melanotic with poorly defined borders (HPDB, 29 cases) 
or amelanotic with sharply demarcated borders (ASDB, 21 
cases). One year after biopsy, of the 48 patients still in the 
study, 20 had lesions that were considered to be stable and 
28 active. Correlations were found between clinical aspects, 
histological findings and vitiligo activity. ASDB lesions 
indicated stability of a lesion, while inflammatory vitiligo, 
trichrome vitiligo and HPDB lesions were considered as 
markers of activity. The authors conclude that a simple clini-
cal examination including a Wood’s lamp may allow reliable 
and efficient evaluation of the stability of vitiligo lesions. Br J 
Dermatol 2013; 168: 265–271.
Effect of FLG mutations and AD on the risk of ICD
Visser et al. investigated the relative contribution and inter-
action of filaggrin gene (FLG) mutations and atopic derma-
titis (AD) in 634 patients with occupational irritant contact 
dermatitis (ICD) and 393 controls. FLG mutations were found 
in 15.9% of the patients with ICD and 8.3% of the con-
trols, with a crude odds ratio (OR) of 2.09 [95% confidence 
interval (CI) 1.33–3.28] for the combined genotype (R501X, 
2282del4, R2447X and S3247X). The adjusted OR for FLG 
mutations, corrected for AD, was 1.62 (95% CI 1.01–2.58). 
Subjects with AD were at approximately three times higher 
risk of developing ICD than controls. There was no evidence 
of an interaction between these two risk factors. Individuals 
with concurrent FLG mutations and AD are at the highest risk 
of developing ICD. Br J Dermatol 2013; 168: 326–332.
Secukinumab in the treatment of moderate-
to-severe plaque psoriasis
The efficacy and safety of different doses of secukinumab, 
a fully human anti-interleukin (IL)-17A IgG1κ monoclo-
nal antibody, in patients with moderate-to-severe plaque 
psoriasis were investigated. After 12 weeks of treatment, 
secukinumab 3 × 150 and 3 × 75 mg resulted in significantly 
higher Psoriasis Area and Severity Index 75% response rates 
vs. placebo (82% and 57% vs. 9%; P < 0.001 and P = 0.002, 
respectively). Two cases of neutropenia (≤ grade 2) were 
reported in the 3 × 150 mg cohort. Br J Dermatol 2013; 168: 
412–421.
Systemic immunosuppressive therapy  
and retinoids for HS
Blok et al. report a systematic review of systemic retinoids 
and immunosuppressants in adults with hidradenitis suppu-
rativa (HS). A total of 87 papers were included, comprising 
518 patients with HS who were treated with systemic reti-
noids, biologic agents or other immunosuppressive agents, 
including colchicine, ciclosporin, dapsone or methotrex-
ate. Overall, the quality of evidence was low and differed 
between the agents, making direct comparisons difficult. 
Infliximab, adalimumab and acitretin were the most effec-
tive systemic agents, although the quality of evidence for 
acitretin was lower than that for infliximab and adalimumab. 
Randomized controlled trials are needed to identify the most 
effective treatment targets and the most effective therapy for 
HS. Br J Dermatol 2013; 168: 243–252.
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